Global Posterior Pituitary for Injection Market Growth 2026-2032
Description
The global Posterior Pituitary for Injection market size is predicted to grow from US$ 243 million in 2025 to US$ 358 million in 2032; it is expected to grow at a CAGR of 5.8% from 2026 to 2032.
Posterior pituitary injection is a drug containing natural or synthetic posterior pituitary hormones (mainly oxytocin and vasopressin). It is mainly used in medical emergency and specific clinical situations to induce and strengthen uterine contractions. It is often used to induce labor during delivery and control postpartum hemorrhage. Oxytocin can promote the contraction of uterine smooth muscle, help speed up the delivery process, and reduce the risk of postpartum hemorrhage.
United States market for Posterior Pituitary for Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Posterior Pituitary for Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Posterior Pituitary for Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Posterior Pituitary for Injection players cover Eisai (Liaoning) Pharmaceutical, Shanghai No. 1 Biochemical & Pharmaceutical, Nanjing Xinbai Pharmaceutical, Anhui Hongye Pharmaceutical, Kamp Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Posterior Pituitary for Injection Industry Forecast” looks at past sales and reviews total world Posterior Pituitary for Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Posterior Pituitary for Injection sales for 2026 through 2032. With Posterior Pituitary for Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Posterior Pituitary for Injection industry.
This Insight Report provides a comprehensive analysis of the global Posterior Pituitary for Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Posterior Pituitary for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Posterior Pituitary for Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Posterior Pituitary for Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Posterior Pituitary for Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Posterior Pituitary for Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Intramuscular Injection
Intravenous Drip
Segmentation by Application:
Lung or Bronchi Bleeding
Gastrointestinal Bleeding
Obstetric Oxytocia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Eisai (Liaoning) Pharmaceutical
Shanghai No. 1 Biochemical & Pharmaceutical
Nanjing Xinbai Pharmaceutical
Anhui Hongye Pharmaceutical
Kamp Pharmaceutical
Chengdu Hepatunn Pharmaceutical
Beijing Science Sun
Shanghai Harvest Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Posterior Pituitary for Injection market?
What factors are driving Posterior Pituitary for Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Posterior Pituitary for Injection market opportunities vary by end market size?
How does Posterior Pituitary for Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Posterior pituitary injection is a drug containing natural or synthetic posterior pituitary hormones (mainly oxytocin and vasopressin). It is mainly used in medical emergency and specific clinical situations to induce and strengthen uterine contractions. It is often used to induce labor during delivery and control postpartum hemorrhage. Oxytocin can promote the contraction of uterine smooth muscle, help speed up the delivery process, and reduce the risk of postpartum hemorrhage.
United States market for Posterior Pituitary for Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Posterior Pituitary for Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Posterior Pituitary for Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Posterior Pituitary for Injection players cover Eisai (Liaoning) Pharmaceutical, Shanghai No. 1 Biochemical & Pharmaceutical, Nanjing Xinbai Pharmaceutical, Anhui Hongye Pharmaceutical, Kamp Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Posterior Pituitary for Injection Industry Forecast” looks at past sales and reviews total world Posterior Pituitary for Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Posterior Pituitary for Injection sales for 2026 through 2032. With Posterior Pituitary for Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Posterior Pituitary for Injection industry.
This Insight Report provides a comprehensive analysis of the global Posterior Pituitary for Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Posterior Pituitary for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Posterior Pituitary for Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Posterior Pituitary for Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Posterior Pituitary for Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Posterior Pituitary for Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Intramuscular Injection
Intravenous Drip
Segmentation by Application:
Lung or Bronchi Bleeding
Gastrointestinal Bleeding
Obstetric Oxytocia
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Eisai (Liaoning) Pharmaceutical
Shanghai No. 1 Biochemical & Pharmaceutical
Nanjing Xinbai Pharmaceutical
Anhui Hongye Pharmaceutical
Kamp Pharmaceutical
Chengdu Hepatunn Pharmaceutical
Beijing Science Sun
Shanghai Harvest Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Posterior Pituitary for Injection market?
What factors are driving Posterior Pituitary for Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Posterior Pituitary for Injection market opportunities vary by end market size?
How does Posterior Pituitary for Injection break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
90 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Posterior Pituitary for Injection by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Posterior Pituitary for Injection by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
